Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3162 combined with Abiraterone in mCRPC
NCT04108247Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui. Primary endpoints: Incidence of Adverse Events at 24 months, Area Under the Curve at 12 months and 2 more. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04108247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108247.